Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
? maybe not so quick, lol?
Also added. Strong company which has been heading in the right direction. What a great opportunity to make some quick money
added
Bought a few myself this morning - but just for a trade after reading Baron's tweets on it:
https://twitter.com/barondaytrading/status/1275350122617090048
In today's RNS, it says the shares were all sold for £23.00 per share to II's. In my experience, II's always get the shares cheap. Also Hikma has bought some back at £23.00 so I would say that the SP should be above £23.00 Therefore buying opportunity?
I wish I had more money, I could have bought at 22.77. Hopefully back around £24 in a few days?
(Alliance News) - German pharmaceutical company Boehringer Ingelheim Invest GmbH intends to sell up to 28 million shares in Hikma Pharmaceuticals PLC, JPMorgan Securities PLC said on Monday.
The Boehringer shares will be offered via an accelerated bookbuild to institutional investors.
Concurrently, Hikma has committed to buy back up to GBP295 million in shares from Boehringer. The purchase price for the buyback shares will be equal to the sale price for the placing shares.
"Hikma has separately today entered into an agreement with Boehringer Ingelheim pursuant to which Hikma will receive a commitment fee of 2% of the aggregate value of the buy back shares acquired at the buy back price," Monday's release said.
Shares in Hikma closed down 1.0% at 2,480.00p in London on Monday.
Boehringer currently owns 40 million ordinary shares in Hikma, representing a 16% stake. Following the successful completion of the placing and the buyback, Boehringer would no longer hold any shares in Hikma.
In its own statement, Hikma said: "The shares being sold by Boehringer Ingelheim were issued by Hikma as part of the consideration for the acquisition of Roxane Laboratories in February 2016. The buy back demonstrates the board's confidence in Hikma's future prospects. Since its initial public offering in 2005, Hikma has delivered a total shareholder return of approximately 926%, exceeding the FTSE 100 total shareholder return of approximately 105%."
Boehringer Ingelheim has engaged Citi and JP Morgan Securities as bookrunners in connection with the placing. Hikma will not receive any proceeds from the placing.
Many thanks Dartron, excellent link and explanation. I had an open limit order sell @ £24.72. Imagine my consternation (well closer to blind panic). Thankfully I've been able to amend the open order, although still a bit puzzled has to why I could, guessing my platform is a couple of steps away from a market maker.
With you on Poly and I'm also biding my time for an entry into CCH, just love not paying stamp.
Correction: RBS had a positive UT of 20M but the SP closed down, showing that -in their case- 20M could not have been bought. (I knew there was something of note about it).
Hi Reg, Thats a good question. I had spent a while looking at it myself yesterday. You are referring to the large UT uncrossing trade, and also that it makes the volume bought look huge! Which is exciting if your invested here! I was quite fortunate as my two biggest shares did this yesterday (HIK and POLY). I tried to do some reading about the UT trade as a lot of time it gets dismissed on these boards as 'not part of the sales'. I noticed that several more UT trades on other shares were also very large yesterday, RBS had one that looks like a very large sell. I dont know why so much was traded at yesterdays close, but I noticed it, as did other people and it does seem unusual. But in brief, the UT trade is the outcome of the closing auction. When the auction closes as many trades as possible for the final price are executed, giving the volume. In my research reading, I did see that Iceberg orders can participate in the auctions and their presence will be revealed as the full size will be shown in the UT. (Iceberg order is a very large order executed in chunks, which normally full size is hidden). So it is unclear whether the entire 31 million was traded or whether part of it was. The good thing is that after the auction there was a 10.9k and 41.6k buy at the new price, which is very comforting if your invested here. That is now the new price (for the weekend, while no one can sell!) until they have another auction on Monday morning. Also, what ever volume of trades happens in the UT, they are both buy and sell, that amount of volume changed hands at that price. In this example, this website considers it a buy because the price of the trade was above the last mid price. Clearly, it is a 'buy' but just making the distinction that this is an exchange of shares.
Part of my research (best info in the video description): https://www.youtube.com/watch?v=sV40TBikG_8
Hi Dartron, can you shed any light on the after close buys last night, or is it something quite common.
Yep, done OK with HIK in the past, lost 7% last time but made 25% the time before.
ULE seems to have lost a little of it's momentum but I might have a little investment in them.
It's good to find a friendly, polite board, there are some very strange characters elsewhere, especially when you question some of their assumptions.
Hi OWLS, good to know your in, i was going to say to you to check out ULE again, I think they are looking very promising, heading for £25 ish I think. Back to HIKK and yes were looking good, I think after a little consolidation here, we should pass the £25 mark soon.
Back in here, generally been showing good positive momentum.
8 Million shares were sold on the last day of May after hours, this took Hikma from its all time high of £26.50 and began its decent down to the low point of £22.50. I wonder if it has taken that long to shift those shares, hence why the price has been depressed. I managed to build up a decent holding of them, averaging just below £24 currently. I may buy a few more on the way up, but judging by the after hours buys today, it looks like we may have begun the accent. I think this company should have a really strong set of results, and possibly once these (interim) and a dividend has been announced we may get back to £26 .
(Sharecast News) - The Sunday Times's Sabah Meddings told readers to 'buy' shares of Hikma Pharmaceuticals, touting it as a potential beneficiary of the White House's 'America First' strategy to promote US manufacturing.
In her 'Inside the City' column, Meddings points out that 1,900 of Hikma's 8,600 staff are based in the US.
And the company sells 10 of the 13 drugs with which patients on ventilators are treated.
The shares have already been boosted this year by news that its heart drug, Vascepa, did not infringe on a rival's patents.
Yet the shares still looked cheap, changing hands on a price-to-earnings multiple of 17.6 against a five-year average of 20.
Analysts from Citi were penciling in a rise in sales from $2.2bn in 2019 to $2.3bn for 2020.
Furthermore, the long-awaited launch of its generic version of GlaxoSmithKline's Advair inhaler was scheduled for the backhalf of 2020, which would likely hand it a chunk of a market worth over $1bn per year.
"It has also underlined its strength by confirming it will pay a final dividend, Buy."
£26.00 per share last week, and today a low of £23.60, through no fault of the company. I sold out just under £26, as part of my strategy, mainly because it was a all time high. I have bought back. I am really glad I got the chance to get back in, as this is one company I feel is a great investment.
hoping for a good finish here again
will look in later now watching ncyt
as sales update due there going by past rns
and thinking another good sales update for their covid 19 testing kits
hoping another good day like yesterday here at hik for a strong finish to this week
and also hoping June month is a strong month for hik
another blue start
looking good
Fingers crossed brought back in today
good buying today
looking like a strong finish
Hang on to them. We are pushing new heights soon.
up for now , and a great recovery from two years ago .should have gone all in,lol
Hikma Pharmaceuticals Plc
HIK
2,426.00 GBX
+95.00 (4.08%)
Last November the market pushed the sp down despite an equally upbeat statement. Let’s see where this goes.
another very good update, should be a good day here.
I wish I had their job...
Hikma Pharmaceuticals: Goldman Sachs downgrades to neutral with a target price of 2,400p.
Previous guidance: August, 2017. Buy - 2,600p.